Work

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder

Year: 2023

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Psychopharmacology

DOI: 10.1177/02698811221149657

Authors: Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Debra Kelsh, Paul Blahunka, Jay Erdman, Mohamad Nour Alsharif, Gerard J Marek

Institutions: Astellas Pharma (United States), Gilgamesh Pharma (United States)

Language: English

Topic: Opioid Use Disorder Treatment

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Institute on Drug Abuse

Award: Evaluation of the Safety and Efficacy of a New Oral Small Molecule GABA-B Receptor Positive Allosteric Modulator (PAM) as an Add-on Maintenance Therapy for Opioid Use Disorder (OUD)

OpenAlex ID: W4319216027

FWCI: 1.019

Cites: 26

Cited by: 4

Related to: 10